AMGN Stock Price Today (October 2026) — Amgen Inc. Analysis & Key Metrics 2026-10-20
Amgen Inc. (AMGN) is trading at $438.94, up 3.29% today (as of October 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $394.98 (10.0% downside).
- Volatility is moderate (26.44% annualized), implying notable price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (9.50% YoY) alongside competitive pressures in the Drug Manufacturers - General space.
AMGN Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
Amgen Inc. - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $280.62B
P/E Ratio
Forward P/E: 17.62
Revenue Growth
Year over Year
Analyst Target
-10.0% downside from target
Key Investor Questions About AMGN
What investors need to know before buying
Based on current market data, AMGN presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 66.27)
- Fundamentals say: Caution warranted (high leverage concerns)
AMGN's growth trajectory depends on its ability to expand within the Drug Manufacturers - General sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - General operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for AMGN investors include debt exposure and competitive dynamics in the Drug Manufacturers - General industry.
- $57.30B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - General.
52-Week Trading Range
Over the past year, AMGN stock traded between $288.00 and $447.03 and currently trades near the high end of that range. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 26.44% annualized volatility and β=0.53, the stock exhibits low sensitivity to market moves—making AMGN suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional ownership with low short interest suggests steadier hands and low immediate risk.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines, coverage and TickZen analysis
Market news
Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?
Dow outperforms as Wall Street rises, healthcare stocks lead gains
2 Dividend Stocks Crushing the Market in 2026 (and Which Ones Can Keep Going)
Stock Market Today: Dow Jumps On U.S.-Iran Hopes; This Warren Buffett Stock Offers Entry (Live Coverage)
AMGEN TO PRESENT AT THE EUROPEAN SOCIETY OF MEDICAL ONCOLOGY CONGRESS 2026
Inhibikase Therapeutics Appoints Scott Wasserman to Board of Directors
Latest TickZen Insights
All insights →No TickZen article on AMGN yet. Our newest analysis:
Explore More Analysis for AMGN
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Nov 3, 2026 (after the close)
Frequently Asked Questions
Common investor questions about Amgen Inc.
Amgen Inc. (AMGN) is currently trading at $438.94. The RSI (14-day) is at 66.3, indicating neutral territory. Wall Street analysts have a consensus "hold" recommendation. The mean analyst price target of $394.98 implies 10.0% downside from current levels. Volatility is moderate at 26.4% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Amgen Inc. (AMGN): The trailing P/E ratio is 23.71, which is in line with broader market averages. The forward P/E is 17.62, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 2.29, above 2.0, suggesting the stock may be overvalued relative to its expected growth. Price-to-Book is 17.65. Price-to-Sales is 5.41. Valuation should be compared to Drug Manufacturers - General industry peers for context, as different sectors trade at different multiples.
Based on 29 analysts covering AMGN, the consensus price target is $394.98. This represents a 10.0% downside from the current price of $438.94. The range spans from a low target of $225.00 to a high target of $500.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "hold". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Amgen Inc. (AMGN) pays a dividend with a current yield of approximately 2.30%. The annualized dividend rate is $9.80 per share. The payout ratio is 60.9%, which is moderate and suggests adequate earnings coverage for the dividend. The most recent ex-dividend date was Aug 21, 2026.
Key risks for Amgen Inc. (AMGN) investors include: 1. Moderate volatility (26.4% annualized)—price swings are notable. 2. Elevated debt levels (debt-to-equity of 4.90x) which could pressure margins in a rising rate environment. 3. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 4. Drug Manufacturers - General sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Amgen Inc.'s (AMGN) current debt and financial health profile: Total debt stands at $57.30B. The debt-to-equity ratio is 4.90x, which is high and could pose financial risk if earnings decline or borrowing costs increase. The current ratio is 1.37, indicating adequate short-term liquidity. The quick ratio is 0.95. The company holds $13.99B in cash and equivalents. Free cash flow is positive at $8.65B, providing a cushion for debt servicing and shareholder returns.